Verdict
Company Name: Abbot Laboratories (Pakistan) Ltd
Ticker: ABOT
Reporting period: Six months and three months ended June 30, 2026
Reporting basis: Unaudited company-level condensed interim financial statements; the cumulative six-month figures received a limited-scope review, while the three-month figures did not.
Abbott Pakistan delivered a stronger first half because pharmaceutical growth and a materially better pharmaceutical gross margin outweighed weakness in nutrition and diagnostics. Net sales rose 4.4% and profit after tax rose 16.9%, but the quality of cash conversion weakened: stock-in-trade climbed, cash paid for tax increased sharply, and operating cash flow fell to Rs662 million. The result is therefore operationally positive but financially mixed—the income statement improved faster than cash generation.
Results at a glance
- H1 net sales were Rs38.03 billion, up 4.4% from Rs36.41 billion. Local sales increased 6.4%, while exports fell 41.4%. Official H1 2026 report
- Gross profit rose 14.5% to Rs14.45 billion. Gross margin expanded to 38.0% from 34.6%, a gain of about 335 basis points, as cost of sales declined slightly despite higher revenue. Official H1 2026 report
- Operating profit increased 19.8% to Rs7.24 billion, lifting the operating margin to 19.0% from 16.6%. Selling and distribution expense still rose 11.2%. Official H1 2026 report
- Profit after tax reached Rs4.14 billion, up 16.9%; EPS rose to Rs42.29 from Rs36.19. Net margin improved to 10.9% from 9.7%. Official H1 2026 report
- Q2 net sales grew 6.6% to Rs20.32 billion and Q2 profit after tax increased 13.2% to Rs2.20 billion. Q2 gross margin was 38.1%, versus 35.5% a year earlier. Official H1 2026 report
- Operating cash flow fell 77.9% to Rs662 million, while stock-in-trade rose 30.8% from the December 2025 year-end and cash declined 29.3% to Rs9.44 billion. Official H1 2026 report
- The board declared an interim cash dividend of Rs12.50 per share, equal to 125% of the Rs10 face value. Official results notice
AlphaGen model readings
These four readings are AlphaGen model outputs, not company-reported financial figures. They are presented as analytical context and should be read alongside the audited or reviewed disclosures.
- Alpha QoQ Score: 65.5
- TTM Performance Score: 93.1
- 3Y Business Perf Score: 96.11
- Sector Leadership Score: 51.25
What improved
- Pharmaceutical economics strengthened. H1 pharmaceutical sales increased 7.6%, but pharmaceutical gross profit rose 24.6%; its gross margin expanded to 39.5% from 34.1%. That spread indicates that mix, pricing and cost efficiency—not volume alone—drove the earnings improvement.
- The consolidated company-level gross-margin gain carried through the income statement. Cost of sales was 0.9% lower even though sales rose 4.4%, allowing operating profit to grow almost five times as quickly as revenue.
- Finance cost remained immaterial at Rs35.6 million and declined 5.5%. With no running-finance utilization disclosed at June 30, higher benchmark rates were not a major drag on the half-year result.
- Other income rose 42.5% to Rs594.0 million. Interest income of Rs443.2 million, versus Rs201.7 million, provided a meaningful secondary contribution without becoming the main earnings engine. Official H1 2026 report
What weakened / needs attention
- Nutrition contracted. H1 nutrition sales declined 7.0% to Rs7.36 billion and segment profit fell 23.4% to Rs1.41 billion. In Q2 alone, nutrition sales fell 8.6% and segment profit fell 32.8%, so stable H1 gross margin did not prevent operating deleverage.
- Diagnostics grew revenue but lost profitability. H1 diagnostics sales rose 12.0% to Rs2.77 billion, yet gross profit fell 13.8% and the segment moved from a Rs54.7 million profit to an Rs8.3 million loss. Growth that consumes margin is not equivalent to economic progress.
- Cash conversion deteriorated. Cash generated from operations before tax fell 15.9%, cash paid for income tax rose 57.7%, and net operating cash flow dropped from Rs3.00 billion to Rs662 million.
- Working capital absorbed balance-sheet capacity. Stock-in-trade increased Rs3.83 billion to Rs16.28 billion, while loans and advances rose to Rs1.60 billion from Rs399 million. Trade and other payables also grew 15.5%, partly financing the asset build.
Current-period comparison
First half: current versus comparable period
- Net sales: Rs38.03 billion versus Rs36.41 billion; change +4.4%. The expansion was domestic-led because local sales grew by Rs2.24 billion while exports fell by Rs618 million.
- Gross profit: Rs14.45 billion versus Rs12.61 billion; change +14.5%. Gross margin expanded roughly 335 basis points, showing that the principal earnings improvement came above the operating-expense line.
- Operating profit: Rs7.24 billion versus Rs6.04 billion; change +19.8%. The margin gain survived higher selling, administrative and other charges, although expenses absorbed part of the gross-profit improvement.
- Profit after tax: Rs4.14 billion versus Rs3.54 billion; change +16.9%. EPS moved in line with profit because the weighted-average share count was unchanged at about 97.9 million shares.
Second quarter: the latest three months
The second quarter confirmed the same direction but with a narrower profit-growth spread. Sales increased 6.6%, gross profit rose 14.5%, operating profit rose 19.6%, and profit after tax rose 13.2%. The quarter also included a Rs159.4 million minimum-tax differential and a 15% increase in operating expenses, which limited the conversion of operating improvement into bottom-line growth. Official H1 2026 report
Where the growth came from
Pharmaceuticals carried the portfolio
Pharmaceuticals generated Rs26.92 billion of H1 sales—about 71% of company revenue—and Rs5.96 billion of segment profit. Sales rose 7.6%, gross profit rose 24.6%, and segment profit rose 35.8%. In Q2, the segment delivered an even stronger 32.9% increase in profit on 9.2% sales growth, making it the decisive contributor to company-level earnings.
The economics are important: pharmaceutical cost of sales declined to Rs16.27 billion from Rs16.49 billion even as revenue increased. Management attributes the company-wide margin improvement to cost optimization and operational efficiency. The segment numbers support that explanation, though the filing does not quantify the contributions from price, volume and product mix separately.
Nutrition remained profitable but smaller
Nutrition produced Rs7.36 billion of H1 sales and Rs1.41 billion of segment profit. Its gross margin stayed near 42.4%, but lower sales meant less gross profit to absorb distribution and administrative costs. This is why segment profit fell much faster than revenue, particularly in Q2.
Diagnostics exposed the difference between revenue and value
Diagnostics revenue rose to Rs2.77 billion, including 24.1% Q2 growth, but H1 gross margin compressed to 11.8% from 15.3%. The segment then slipped into a small loss. Readers should therefore track diagnostics gross profit and segment result, not celebrate top-line growth in isolation.
Exports became less diversified
Pakistan sales rose to Rs37.15 billion, while Afghanistan sales fell 80.4% to Rs167.6 million and were zero in Q2. Switzerland-related sales increased to Rs672.4 million, but they were not enough to prevent overall exports from dropping 41.4%. The domestic franchise now explains an even larger share of reported growth. Official H1 2026 report
Margin mechanics and operating costs
Company gross margin reached 38.0% because sales increased while total cost of sales edged down. This was not uniform across the portfolio: pharmaceuticals improved sharply, nutrition was stable, and diagnostics weakened. The group-level margin therefore reflects a favorable contribution mix as well as efficiency.
Below gross profit, selling and distribution expense rose 11.2% to Rs6.15 billion, faster than revenue. Administration increased 21.6% to Rs776.1 million, and other charges rose 7.4% to Rs887.4 million. Within other charges, expected credit-loss expense on trade debts was Rs174.0 million, while exchange loss fell to Rs46.0 million from Rs138.2 million. The weaker exchange-loss line helped, but it did not eliminate cost inflation elsewhere.
Other income partially offset these pressures. Interest income more than doubled, consistent with the sizable cash balance. That contribution is economically less durable than gross profit from core products because it depends on liquidity levels and deposit returns.
Cash flow, working capital and balance-sheet capacity
The cash-flow statement is the main counterweight to the stronger profit result. Cash generated from operations before taxes was Rs4.58 billion, down from Rs5.44 billion. After Rs3.58 billion of income-tax payments and Rs159.4 million of minimum-tax differential payments, operating cash flow was only Rs662.4 million.
Capital expenditure was Rs1.11 billion, so operating cash flow did not fully fund investment in property, plant and equipment. Interest receipts narrowed the investing outflow to Rs626.4 million. Financing outflow was Rs3.94 billion, dominated by Rs3.86 billion of dividends paid, and total cash fell by Rs3.90 billion during the half.
At June 30, current assets were Rs32.82 billion and current liabilities Rs15.04 billion, leaving about Rs17.78 billion of working capital—broadly unchanged from December. The composition worsened, however: cash was lower and stock-in-trade was higher. Provision against obsolete and slow-moving raw and packing materials increased to Rs347.0 million, an indicator that inventory quality deserves attention alongside inventory quantity. Official H1 2026 report
The balance sheet still shows substantial resilience. Equity was Rs32.10 billion, total assets were Rs48.76 billion, no running finance was utilized, and disclosed short-term facilities totaled Rs8.10 billion. Commitments included Rs857.7 million of capital expenditure and Rs1.58 billion under letters of credit, which make future cash conversion relevant even without current bank borrowing.
Dividend and capital allocation
The Rs12.50-per-share interim dividend follows Rs3.86 billion of cash dividends paid during the half, largely reflecting the Rs40-per-share final dividend for 2025. The announced interim distribution is separate from H1 cash flow because it was declared after the reporting date. Investors should distinguish accounting profit, cash generated during the period and later distributions when judging payout sustainability.
Abbott Asia Investments holds 77.90% of the company, with Abbott Laboratories in the United States identified as the ultimate parent. Related-party purchases remained substantial at Rs8.73 billion, while technical service fees were Rs197.2 million. This group relationship supports access to products and know-how, but it also makes foreign-currency availability, import costs and transfer-pricing-related cash flows relevant. Official H1 2026 report
Tax, regulation and other judgment areas
Reported profit included a Rs159.4 million minimum-tax differential in Q2 and a total tax charge of Rs2.90 billion for H1. Finance costs were small, so tax—not interest—was the larger bridge from operating profit to net profit. Cash tax was even heavier than the income-statement charge, helping explain the gap between earnings and operating cash flow.
The filing describes several tax demands under appeal, including amounts of Rs242.1 million, Rs477.7 million and Rs186.4 million. The company has not recorded provisions based on professional advice and favorable expectations. These are disclosed contingencies rather than current-period expenses, but they remain outcomes to monitor rather than amounts to treat as certain losses.
Management described the regulatory, fiscal and macroeconomic landscape as fluid and welcomed changes affecting nonessential drugs outside the National Essential Medicines List. It also highlighted geopolitical tension, oil-related inflation, demand conditions and currency stability as risks. These are management statements, not quantified forecasts. Official H1 2026 report
How to read the next result
- Pharmaceutical sales and gross margin: this segment supplies most revenue and nearly all incremental profit, so a reversal in its margin would have an outsized effect.
- Nutrition volume and segment profit: gross margin is resilient, but lower sales are causing operating deleverage. A recovery must show up in both revenue and segment result.
- Diagnostics gross margin: revenue growth needs to translate into gross profit and a positive segment result before it can be considered value-accretive.
- Operating cash flow relative to profit: compare cash generated from operations, tax paid and working-capital movements with profit after tax.
- Stock-in-trade and provisions: monitor both the inventory balance and write-downs for obsolete or slow-moving items.
- Domestic versus export sales: Afghanistan’s decline made growth more dependent on Pakistan, increasing exposure to local regulation, demand and pricing.
What to monitor next
- Whether H2 pharmaceutical margin remains near the improved H1 level or normalizes as mix, imported inputs and promotional spending change.
- Whether nutrition returns to growth and whether diagnostics converts higher sales into positive segment earnings.
- Whether inventory falls from Rs16.28 billion and cash generation closes the gap with reported profit.
- The cash effect of the interim dividend, capital commitments and letters of credit.
- Any resolution of tax appeals and any regulatory change affecting drug pricing, essential-medicine classification or imported inputs.
- Rupee stability, inflation and supply-chain conditions, particularly because a meaningful portion of purchases is linked to group companies.